CN114848603B - Vardenafil freeze-dried flash-release tablet and preparation process thereof - Google Patents

Vardenafil freeze-dried flash-release tablet and preparation process thereof Download PDF

Info

Publication number
CN114848603B
CN114848603B CN202210441748.XA CN202210441748A CN114848603B CN 114848603 B CN114848603 B CN 114848603B CN 202210441748 A CN202210441748 A CN 202210441748A CN 114848603 B CN114848603 B CN 114848603B
Authority
CN
China
Prior art keywords
vardenafil
minutes
freeze
pullulan
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210441748.XA
Other languages
Chinese (zh)
Other versions
CN114848603A (en
Inventor
蔡孟杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hubei Feirui Biopharmaceutical Co ltd
Original Assignee
Hubei Feirui Biopharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hubei Feirui Biopharmaceutical Co ltd filed Critical Hubei Feirui Biopharmaceutical Co ltd
Priority to CN202210441748.XA priority Critical patent/CN114848603B/en
Publication of CN114848603A publication Critical patent/CN114848603A/en
Application granted granted Critical
Publication of CN114848603B publication Critical patent/CN114848603B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a vardenafil freeze-dried flash-released tablet and a preparation method thereof, wherein the freeze-dried flash-released tablet comprises the following components in parts by weight: 5-15 parts of vardenafil, 14-17.5 parts of mannitol, 16.5-18.5 parts of pullulan, 0.3-1.4 parts of sucralose and a proper amount of water. The vardenafil freeze-dried flash-release tablet provided by the invention does not need water when being taken, and is beneficial to protecting the privacy of men. The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a vardenafil freeze-dried flash-release tablet and a preparation process thereof.

Description

Vardenafil freeze-dried flash-release tablet and preparation process thereof
Technical Field
The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a vardenafil freeze-dried flash-release tablet and a preparation process thereof.
Background
Vardenafil (Vardenafil) is a drug in the field of treatment of Erectile Dysfunction (ED), developed over the years by Bayer (Bayer) and ghatti (Glaxo Smith Kline) in germany, and acts by inhibiting phosphodiesterase type 5 (PDE-5), which has the following advantages compared to sildenafil (pego): the dosage is small, only 20mg (120 mg-150mg of sildenafil is needed). The medicine takes effect within 15 to 30 minutes, reaches the peak value within 30 to 60 minutes, has the duration of more than 6 hours and has small side effect.
The dosage forms of vardenafil on the market at present are common tablets prepared by a tabletting method, and the vardenafil is taken by drinking water, so that the vardenafil is not very convenient to use for some men to want to protect personal privacy under certain conditions.
Disclosure of Invention
The invention aims to provide vardenafil freeze-dried flash-release tablets and a preparation process thereof, so as to solve the problems in the background technology.
In order to solve the technical problems, the vardenafil freeze-dried flash release tablet provided by the invention comprises the following components in parts by weight: 5-15 parts of vardenafil, 14-17.5 parts of mannitol, 16.5-18.5 parts of pullulan, 0.3-1.4 parts of sucralose and a proper amount of water.
In addition, the invention also discloses a preparation process of the vardenafil freeze-dried flash release tablet, which comprises the following steps:
(1) Dissolving pullulan, adding a proper amount of purified water into a stirring kettle, heating to 55 ℃, weighing the pullulan with the prescription amount, adding the pullulan into the stirring kettle, stirring to completely dissolve the pullulan, and then cooling to room temperature;
(2) Preparing an emulsion, namely respectively weighing the prescription amount of sucralose, mannitol and vardenafil, adding the sucralose, mannitol and vardenafil into the feed liquid prepared in the step (1), stirring until the components are completely dissolved, and adding a proper amount of water to fix the volume so that the concentrations of the vardenafil, mannitol, pullulan and sucralose are 17-25g/L, 25-40g/L, 30-40g/L and 1-2g/L;
(3) Emulsifying and degassing, namely pouring the feed liquid obtained in the step (2) into an emulsifying machine for emulsification, wherein the rotating speed of the emulsifying machine is 5000-12000r/min, and then degassing the emulsified feed liquid under vacuum for 15min;
(4) Filling, namely sub-packaging the feed liquid obtained in the step (3) into foam holes of an aluminum plastic foam plate at a ratio of 0.5 ml/piece;
(5) Quick freezing, namely placing the bubble cap plate filled with the feed liquid into a liquid nitrogen tunnel at the temperature of minus 100 ℃ for pre-freezing for 15 minutes;
(6) Freeze-drying, namely transferring the pre-frozen bubble cap plate into a plate layer of a freeze dryer for freeze-drying, and running the following curves: -35 ℃ for 60 minutes; -25 ℃ for 330 minutes; -20 ℃ for 100 minutes; -15 ℃ for 120 minutes; raising the temperature from-15 ℃ to-5 ℃ and keeping the temperature at-5 ℃ for 60 minutes; -5-25 ℃ for 30 minutes, 25 ℃ for 210 minutes;
(7) Sealing, taking out the bubble plate from the freeze dryer, and coating film on the sealing machine for packaging and cutting.
The invention adopts the structure to obtain the beneficial effects as follows: the vardenafil freeze-dried flash-released tablet provided by the invention is taken without water, is dissolved in an inlet, is completely disintegrated within 3 seconds, has good taste, has no gritty feel and has no peculiar smell. Can completely meet the needs of some male ED patients in certain situations for protecting personal privacy.
Detailed Description
The technical scheme of the invention is further described in detail in the following with specific implementation, and all parts of the technical features of the invention, which are not described in detail, are adopted in the prior art.
The present invention will be described in further detail with reference to examples.
1. Examples of formulations
Example 1
Vardenafil lyophilized flash tablet formulation:
the preparation process of the vardenafil freeze-dried flash release tablet comprises the following steps:
(1) Dissolving pullulan, adding a proper amount of purified water into a stirring kettle, heating to 55 ℃, weighing the pullulan with the prescription amount, adding the pullulan into the stirring kettle, stirring to completely dissolve the pullulan, and then cooling to room temperature;
(2) Preparing an emulsion, namely respectively weighing the prescription amount of sucralose, mannitol and vardenafil, adding the sucralose, mannitol and vardenafil into the feed liquid prepared in the step (1), stirring until the components are completely dissolved, and adding a proper amount of water to fix the volume so that the concentrations of the vardenafil, mannitol, pullulan and sucralose are 17-25g/L, 25-40g/L, 30-40g/L and 1-2g/L;
(3) Emulsifying and degassing, namely pouring the feed liquid obtained in the step (2) into an emulsifying machine for emulsification, wherein the rotating speed of the emulsifying machine is 5000-12000r/min, and then degassing the emulsified feed liquid under vacuum for 15min;
(4) Filling, namely sub-packaging the feed liquid obtained in the step (3) into foam holes of an aluminum plastic foam plate at a ratio of 0.5 ml/piece;
(5) Quick freezing, namely placing the bubble cap plate filled with the feed liquid into a liquid nitrogen tunnel at the temperature of minus 100 ℃ for pre-freezing for 15 minutes;
(6) Freeze-drying, namely transferring the pre-frozen bubble cap plate into a plate layer of a freeze dryer for freeze-drying, and running the following curves: -35 ℃ for 60 minutes; -25 ℃ for 330 minutes; -20 ℃ for 100 minutes; -15 ℃ for 120 minutes; raising the temperature from-15 ℃ to-5 ℃ and keeping the temperature at-5 ℃ for 60 minutes; -5-25 ℃ for 30 minutes, 25 ℃ for 210 minutes;
(7) Sealing, taking out the bubble plate from the freeze dryer, coating film on the sealing machine for packaging, cutting, and preparing 1000 tablets from the ingredients of the prescription.
Example 2
Vardenafil lyophilized flash tablet formulation:
the preparation process is as in example 1.
Example 3
Vardenafil lyophilized flash tablet formulation:
the preparation process is as in example 1.
Example 4
Vardenafil lyophilized flash tablet formulation:
the preparation process is as in example 1.
Example 5
Vardenafil lyophilized flash tablet formulation:
the preparation process is as in example 1.
Example 6
Vardenafil lyophilized flash tablet formulation:
the preparation process is as in example 1.
Example 7
Vardenafil lyophilized flash tablet formulation:
the preparation process is as in example 1.
Example 8
Vardenafil lyophilized flash tablet formulation:
the preparation process is as in example 1.
2. Evaluation result
The preparation process conditions of examples 1 to 5 are the same, the ratios of vardenafil and sucralose in the formulation are the same, the only changes are the amounts of mannitol and pullulan, and examples 1 to 5 can be used to evaluate the effect of mannitol and pullulan on the formation of vardenafil lyophilized flash tablets.
The experimental results are as follows:
sample of Whether or not to split Whether or not to collapse Degree of shrinkage of the sheet Disintegration time
Example 1 Whether or not Whether or not 0 2.3s
Example 2 Whether or not Whether or not 0 2.6s
Example 3 Whether or not Whether or not 0 2.2s
Example 4 Is that Whether or not 10.7% /
Example 5 Is that Is that / /
Conclusion: the pullulan accounts for 3.3 to 3.7 percent of the total weight of the pullulan; when the mannitol accounts for 2.8-3.5%, the obtained freeze-dried flash tablet is well formed, has no phenomena of cracking and collapse, and disintegrates rapidly and completely within 3 seconds.
The invention and its embodiments have been described above with no limitation, and the examples shown are only one of the embodiments of the invention and are not limited thereto in practice. In summary, those skilled in the art, having benefit of this disclosure, will appreciate that many changes can be made without departing from the spirit and scope of the invention as disclosed herein.

Claims (3)

1. The vardenafil freeze-dried flash release tablet is characterized by comprising the following components in parts by weight: 5-15 parts of vardenafil, 14-17.5 parts of mannitol, 16.5-18.5 parts of pullulan, 0.3-1.4 parts of sucralose and a proper amount of water.
2. A method for preparing the vardenafil freeze-dried flash-release tablet according to claim 1, comprising the following steps:
(1) Dissolving pullulan, adding a proper amount of purified water into a stirring kettle, heating to 55 ℃, weighing the pullulan with the prescription amount, adding the pullulan into the stirring kettle, stirring to completely dissolve the pullulan, and then cooling to room temperature;
(2) Preparing an emulsion, namely respectively weighing the prescription amount of sucralose, mannitol and vardenafil, adding the sucralose, mannitol and vardenafil into the feed liquid prepared in the step (1), stirring until the components are completely dissolved, and adding a proper amount of water to fix the volume so that the concentrations of the vardenafil, mannitol, pullulan and sucralose are 17-25g/L, 25-40g/L, 30-40g/L and 1-2g/L;
(3) Emulsifying and degassing, namely pouring the feed liquid obtained in the step (2) into an emulsifying machine for emulsification, wherein the rotating speed of the emulsifying machine is 5000-12000r/min, and then degassing the emulsified feed liquid under vacuum for 15min;
(4) Filling, namely sub-packaging the feed liquid obtained in the step (3) into foam holes of an aluminum plastic foam plate at a ratio of 0.5 ml/piece;
(5) Quick freezing, namely placing the bubble cap plate filled with the feed liquid into a liquid nitrogen tunnel at the temperature of minus 100 ℃ for pre-freezing for 15 minutes;
(6) Lyophilizing, namely transferring the pre-frozen bubble cap plate into a plate layer of a lyophilizing machine for lyophilizing;
(7) Sealing, taking out the bubble plate from the freeze dryer, and coating film on the sealing machine for packaging and cutting.
3. The method for preparing vardenafil freeze-dried flash-release tablets according to claim 2, wherein the freeze dryer in step (5) operates the following curve: -35 ℃ for 60 minutes; -25 ℃ for 330 minutes; -20 ℃ for 100 minutes; -15 ℃ for 120 minutes; raising the temperature from-15 ℃ to-5 ℃ and keeping the temperature at-5 ℃ for 60 minutes; -5-25 ℃ for 30 minutes, 25 ℃ for 210 minutes.
CN202210441748.XA 2022-04-25 2022-04-25 Vardenafil freeze-dried flash-release tablet and preparation process thereof Active CN114848603B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210441748.XA CN114848603B (en) 2022-04-25 2022-04-25 Vardenafil freeze-dried flash-release tablet and preparation process thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210441748.XA CN114848603B (en) 2022-04-25 2022-04-25 Vardenafil freeze-dried flash-release tablet and preparation process thereof

Publications (2)

Publication Number Publication Date
CN114848603A CN114848603A (en) 2022-08-05
CN114848603B true CN114848603B (en) 2023-12-12

Family

ID=82632891

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210441748.XA Active CN114848603B (en) 2022-04-25 2022-04-25 Vardenafil freeze-dried flash-release tablet and preparation process thereof

Country Status (1)

Country Link
CN (1) CN114848603B (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070102065A (en) * 2006-04-13 2007-10-18 한미약품 주식회사 Fast acting formulation of vardenafil
CN112972405A (en) * 2019-12-02 2021-06-18 北京兴源联合医药科技有限公司 Tadalafil freeze-dried orally disintegrating tablet and preparation method thereof
CN112972404A (en) * 2019-12-02 2021-06-18 北京兴源联合医药科技有限公司 Sildenafil freeze-dried orally disintegrating tablet and preparation method thereof
CN113081981A (en) * 2021-04-06 2021-07-09 北京菲瑞阳林医药技术研发有限公司 Lactase freeze-drying flash-release tablet and preparation method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005009240A1 (en) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Dosage forms with improved pharmacokinetic properties

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070102065A (en) * 2006-04-13 2007-10-18 한미약품 주식회사 Fast acting formulation of vardenafil
CN112972405A (en) * 2019-12-02 2021-06-18 北京兴源联合医药科技有限公司 Tadalafil freeze-dried orally disintegrating tablet and preparation method thereof
CN112972404A (en) * 2019-12-02 2021-06-18 北京兴源联合医药科技有限公司 Sildenafil freeze-dried orally disintegrating tablet and preparation method thereof
CN113081981A (en) * 2021-04-06 2021-07-09 北京菲瑞阳林医药技术研发有限公司 Lactase freeze-drying flash-release tablet and preparation method thereof

Also Published As

Publication number Publication date
CN114848603A (en) 2022-08-05

Similar Documents

Publication Publication Date Title
EP1357870B1 (en) Bioadhesive cell foam film of sustained-release delivery
US10548839B2 (en) Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
CN1293867C (en) Drug preparations
JPH05507085A (en) Pharmaceutical preparations containing n-glycofurols and n-ethylene glycols
CN1251758A (en) Oral medicinal preparation
ES2426963T3 (en) Film preparation with oily substances for oral administration
CN104168895A (en) High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient
CN103974695A (en) Bitter taste masked oral thin film formulation of sildenafil citrate
CN102784169A (en) In situ gel preparation loaded with Kangfuxin and its preparation method and use
CN101889974A (en) Chitosan contraceptive gel and preparation method thereof
WO2019205700A1 (en) Edaravone pharmaceutical composition
EP1048297B1 (en) Use of polyethylene glycol for reducing of intestinal gas, cramping and anorectal irritation
CN114848603B (en) Vardenafil freeze-dried flash-release tablet and preparation process thereof
KR102064864B1 (en) Topical injectable composition
AU2004251018A1 (en) Transmucosal form of administration with reduced mucosal irritation
US20200282004A1 (en) Solid Pharmaceutical Compositions for Treating HCV
CN102000339A (en) Drug carrier capable of realizing sustained release of drug
TW202019394A (en) Dosage form for insertion into the mouth
CN103417562A (en) Nifuratel-nysfungin vaginal soft capsule and preparation method thereof
CN102048711B (en) Granisetron membrane preparation and preparation method
CN112022902A (en) Preparation method and application of carbon-point modified fluconazole eucalyptus oil microemulsion gel
CN104490851A (en) Iseganan quick-release film agent
CN114432329A (en) Application of geniposide in preparation of medicine for treating psoriasis
Pietrzak et al. Combined oral contraception in women after renal transplantation
US11246866B2 (en) Solid pharmaceutical compositions for treating HCV

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20231115

Address after: Building 3, No. 12, Wuchu Avenue, Fankou Street, Echeng District, Ezhou, Hubei Province, 436000

Applicant after: Hubei Feirui Biopharmaceutical Co.,Ltd.

Address before: 061000 exhibition culture industrial park, Cangzhou Economic Development Zone, Jiefang East Road, Cangzhou Economic Development Zone, Cangzhou City, Hebei Province

Applicant before: Hebei Feirui Biotechnology Co.,Ltd.

GR01 Patent grant
GR01 Patent grant